Terns Pharmaceuticals, Inc. (TERN)
| Market Cap | 429.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -39.90M |
| Shares Out | 23.89M |
| EPS (ttm) | -1.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $17.13 |
| Previous Close | $18.54 |
| Change ($) | -1.41 |
| Change (%) | -7.61% |
| Day's Open | 19.89 |
| Day's Range | 15.73 - 21.00 |
| Day's Volume | 167,072 |
| 52-Week Range | 14.83 - 27.44 |
FOSTER CITY, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio ...
FOSTER CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio ...
FOSTER CITY, Calif. -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
FOSTER CITY, Calif.--Terns Pharmaceuticals, Inc. (“Terns” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination th...
Terns Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.
Terns Pharmaceuticals, a Phase 2 biotech developing small molecule therapies for NASH, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy...
About TERN
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. NASH is a severe form of non-alcoholic fatty liver disease, or NAFLD, that affects up to 15 million people in the United States, and up to 6% of the global population, for which there is currently no approved therapy in the United States or Europe. NASH is a multifaceted disease that involves thre... [Read more...]
| Industry Medicinal and Botanical Manufacturing | IPO Date Feb 5, 2021 |
| CEO Senthil Sundaram | Employees 30 |
| Stock Exchange NASDAQ | Ticker Symbol TERN |